{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(2)"],"submitter":["Hunnicutt J"],"pubmed_abstract":["<h4>Objective</h4>One key target of treating patients with systemic lupus erythematosus (SLE) is to prevent organ damage. This analysis quantified the association between time spent in four specific SLE low disease activity (LDA) states and organ damage rate.<h4>Methods</h4>This retrospective real-world data analysis (GSK Study 207168), undertaken to help contextualise the BLISS-BELIEVE clinical trial, included adults with SLE enrolled for≥1 year in the Hopkins Lupus Cohort and treated with standard therapy in a specialist care centre between 1987 and 2019. LDA states (Lupus Low Disease Activity State (LLDAS), disease control, clinical and complete remissions) were defined using SLE Disease Activity Index (SLEDAI)/Physician Global Assessment scores, prednisone-equivalent dose and medicatio"],"journal":["Lupus science & medicine"],"pagination":["e001206"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11647352"],"repository":["biostudies-literature"],"pubmed_title":["Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins Lupus Cohort."],"pmcid":["PMC11647352"],"pubmed_authors":["Magder L","Richards A","Petri MA","Georgiou ME","Hunnicutt J","Goldman D","Quasny H"],"additional_accession":[]},"is_claimable":false,"name":"Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins Lupus Cohort.","description":"<h4>Objective</h4>One key target of treating patients with systemic lupus erythematosus (SLE) is to prevent organ damage. This analysis quantified the association between time spent in four specific SLE low disease activity (LDA) states and organ damage rate.<h4>Methods</h4>This retrospective real-world data analysis (GSK Study 207168), undertaken to help contextualise the BLISS-BELIEVE clinical trial, included adults with SLE enrolled for≥1 year in the Hopkins Lupus Cohort and treated with standard therapy in a specialist care centre between 1987 and 2019. LDA states (Lupus Low Disease Activity State (LLDAS), disease control, clinical and complete remissions) were defined using SLE Disease Activity Index (SLEDAI)/Physician Global Assessment scores, prednisone-equivalent dose and medicatio","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-04T01:31:20.052Z","creation":"2025-04-04T01:31:20.052Z"},"accession":"S-EPMC11647352","cross_references":{"pubmed":["39663154"],"doi":["10.1136/lupus-2024-001206"]}}